TRUFFLE-CAPITAL
8.7.2021 08:02:05 CEST | Business Wire | Press release
Created by the private equity firm Truffle Capital and the research and consulting firm teknowlogy | CXP-PAC, the Truffle 100 2021 provides an overview of the French software industry by analyzing the activity of the top 100 companies in the sector during 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210707005107/en/
- This period was marked by several notable highlights: with a +6.6% increase, the growth in activity in the sector reached record highs, i.e. €11.6 billion; however, a record number of companies (33%) posted a fall in revenue.
- For the first time since 2013, the difference between the 50th and the 100th publishers decreased; but with 35% of the sector's revenue in 2020, the weighting of the company in first place continues to grow (+2 pts in 2020)
The Truffle 100 clearly shows that the anticipated market shock has not affected the whole software industry. Nevertheless, the companies have put forward a shared vision of the future of the market.
- The cloud is now considered by 92% of companies as the trend that will provide momentum in the sector over the coming years. This new trend, driven by the crisis, recorded a growth of +16 pts compared to the ranking published in 2020.
- In light of this situation, three-quarters of the companies plan to increase their workforce, and three-quarters also plan to ramp up their R&D projects.
Commenting on this 16th edition of Truffle 100, Cédric Ô, French Secretary of State for the Digital Economy, concluded: "In similar fashion to previous years, the development of the sector has been achieved by the long-standing efforts of its stakeholders and their capacity to anticipate the major technological breakthroughs which are, in the digital industry, more frequent and clearer to distinguish than in other industries ".
Bernard-Louis Roques, Managing Director and co-founder of Truffle Capital declared: "At a time when the ability to respond to events and the management of expertise proved vital, the French software industry played a civic role and created jobs on the domestic marke t".
Nadia Idrissi, Chairwoman of teknowlogy | CXP-PAC, added: "Highly topical themes such as the cloud, cybersecurity and the remote workplace have driven the market and allowed the majority of publishers, who are - on the whole - well prepared, to deliver revenue growth. [...] Companies using software solutions are picking up the pace of this forced march towards major digital transformation investments, and this also applies to industrial processes ".
The 16th edition of the Truffle 100 is available on the following website: https://www.truffle100.fr/
About Truffle Capital
Founded in 2001, Truffle Capital is an independent European venture capital company, specializing in life sciences (MedTech and Biotech) and breakthrough technologies in the IT sectors (FinTech and InsurTech). Truffle Capital’s mission is to support the creation and development of young innovative companies capable of becoming tomorrow’s leaders. The company is chaired by Patrick Kron and managed by Dr Philippe Pouletty and Bernard-Louis Roques, co-founders and General Managers. Truffle Capital manages €700 million in assets. Since its creation, it has raised nearly €1.1 billion and has supported over 75 companies in the digital technology and life sciences sectors. In 2019, Truffle Capital announced it had raised nearly €400 million in new institutional funds, including €140 million in Fintech/Insurtech.
Further information: www.truffle.com — Twitter: @trufflecapital
About teknowlogy Group
teknowlogy | CXP-PAC teknowlogy | CXP-PAC is the leading European independent analysis and consulting firm in the field of software, IT services and digital transformation. As a privileged partner of European user companies, it offers them assistance in defining their digital strategy, managing projects and reducing the risks linked to technological choices and their implementation.
Owing to its knowledge of market trends and user-company expectations, teknowlogy | CXP-PAC helps software publishers and ESNs to better establish, execute and promote their own strategy in line with market expectations and in anticipation of future needs.
Capitalizing on more than 40 years of experience, teknowlogy | CXP-PAC has a network of 50 experts based in Paris, Munich, Bucharest, and London.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005107/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom